この記事を読む

ペメトレキセド維持療法の投与間隔を延ばしても予後に悪影響を与えない?

Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experie…

この記事を読む

KRASと併存するSTK11とKEAP1変異の免疫療法における意味

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected …

この記事を読む

術後補助化学療法の維持療法;IMpower010

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a r…

この記事を読む

抗がん剤治療中でもCovid19ワクチンの効果は出るのか?

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Stud…

この記事を読む

エルロチニブ+ラムシルマブ、EGFR遺伝子変異別のサブグループ解析

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small C…

この記事を読む

EGFR-TKI耐性後の免疫治療 vs 殺細胞性抗がん剤

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EG…

この記事を読む

MET14skippingのテポチニブ治療は背景に依存するか

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION…

この記事を読む

SP142と22C3:同じか異なるのか

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell L…

この記事を読む

EGFR遺伝子変異陽性、切除後の予後は

Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM…

この記事を読む

EGFR遺伝子変異陽性の術後補助化学療法の層別化

Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small C…